Stereocontrolled Total Synthesis of (+)-Paraherquamide B

Timothy D. Cushing, Juan F. Sanz-Cervera,[†] and Robert M. Williams

> Department of Chemistry Colorado State University Fort Collins, Colorado 80523

Received July 12, 1993

The paraherquamides are complex, heptacyclic, toxic mold metabolites with potent anthelmintic activity isolated from various Penicillium sp. The parent and most potent derivative, paraherquamide A (1), was first isolated from Penicillium paraherquei in 1980 by Yamazaki.¹ The simplest member, paraherquamide B (2), plus five other structurally related paraherquamides (C-G) were isolated from Pencillium charlesii (ATCC 20841) in 1990 at Merck & Co.^{2,3} and concomitantly at SmithKline Beecham.4



Recent interest in the paraherquamides has come from the finding that this class of alkaloids displays potent anthelmintic and antinematodal properties.^{2,4-6} There are essentially three classes of broad spectrum anthelmintics currently in use: the benzimidazoles, the levamisoles/morantels, and the avermectins/ milbemycins. Unfortunately, the first two groups have lost much of their utility due to the appearance of drug resistance built up by the helminths.^{6a,7} More recently, drug resistance to the avermectins has been observed in various parasites.⁸ The paraherquamides represent an entirely new structural class of antiparasitic agents that promise to play a significant role in the near future. The relatively low culture yields of obtaining paraherquamides for biological study have slowed the development of these agents.

In connection with our ongoing studies on the biosynthesis of the structurally related metabolites the brevianamides,⁹ we wish

[†] On leave from the Department of Organic Chemistry, University of Valencia, Spain.

(1) (a) Yamazaki, M.; Fujimoto, H.; Okuyama, E.; Ohta, Y. Proc. Jpn. Assoc. Mycotoxicol. 1980, 10, 27. (b) Yamazaki, M.; Okuyama, E. Tetrahedron Lett. 1981, 22, 135.

(2) (a) Blizzard, T. A.; Marino, G.; Mrozik, H.; Fisher, M. H.; Hoogsteen, K.; Springer, J. P. J. Org. Chem. 1989, 54, 2657. (b) Blizzard, T. A.; Mrozik, H.; Fisher, M. H.; Schaeffer, J. M. J. Org. Chem. 1990, 55, 2256. (c) Blizzard, T. A.; Margiatto, G.; Mrozik, H.; Schaeffer, J. M.; Fisher, M. H. Tetrahedron Lett. 1991, 32, 2437. (d) Blizzard, T. A.; Margiatto, G.; Mrozik, H.; Schaeffer, J. M.; Fisher, M. H. Tetrahedron Lett. 1991, 32, 2441. (e) Blizzard, T. A.; Rosegay, A.; Mrozik, H.; Fisher, M. H. J. Labelled Compd. Radiopharm. 1989, 28, 461.

(3) Ondeyka, J. D.; Goegelman, R. T.; Schaeffer, J. M.; Kelemen, L. J. Antibiot. 1990, 43, 1375.

(4) Blanchflower, S. E.; Banks, R. M.; Everett, J. R.; Manger, B. R.; Reading, C. J. Antibiot. 1991, 44, 492.

 (5) Ostlind, D. A.; Mickle W. G.; Ewanciw, D. V.; Andriuli, F. J.; Campbell,
 W. C.; Hernandez, S.; Mochaeles, S.; Munguira, E. Res. Vet. Sci. 1990, 48, 260.

(6) (a) Shoop, W. L.; Egerton, J. R.; Eary, C. H.; Suhayda, D. J. Parasitol. **1990**, *76*, 349. (b) Shoop, W. L.; Michael, B. F.; Haines, H. W.; Eary, C. H. Vet. Parasitol. **1992**, *43*, 259. (c) Schaeffer, J. M.; Blizzard, T. A.; Ondeyka, J.; Goegelman, R.; Sinclair, P. J.; Mrozik, H. Biochem. Pharmacol. **1992**, *43*, 259. (c) Schaeffer, J. M.; Sinclair, P. J.; Mrozik, H. Biochem. Pharmacol. **1992**, *43*, 259. (c) Schaeffer, J. M.; Sinclair, P. J.; Mrozik, H. Biochem. Pharmacol. **1992**, *43*, 259. (c) Schaeffer, J. M.; Sinclair, P. J.; Mrozik, H. Biochem. Pharmacol. **1992**, *43*, 259. (c) Schaeffer, J. M.; Sinclair, P. J.; Mrozik, H. Biochem. Pharmacol. **1992**, *43*, 259. (c) Schaeffer, J. M.; Sinclair, P. J.; Mrozik, H. Biochem. Pharmacol. **1992**, *43*, 259. (c) Schaeffer, J. M.; Sinclair, P. J.; Mrozik, H. Biochem. Pharmacol. **1992**, *43*, 259. (c) Schaeffer, J. M.; Sinclair, P. J.; Mrozik, H. Biochem. Pharmacol. **1992**, *43*, 259. (c) Schaeffer, J. M.; Sinclair, P. J.; Mrozik, H. Biochem. Pharmacol. **1992**, *43*, 259. (c) Schaeffer, J. M.; Sinclair, P. J.; Mrozik, H. Biochem. Pharmacol. **1992**, *43*, 259. (c) Schaeffer, J. M.; Sinclair, P. J.; Mrozik, H. Biochem. Pharmacol. **1992**, *43*, 259. (c) Schaeffer, J. M.; Mrozik, H. Biochem. Pharmacol. **1992**, *43*, 259. (c) Schaeffer, J. M.; Mrozik, H. Biochem. Pharmacol. **1992**, *43*, 259. (c) Schaeffer, J. M.; Mrozik, H. Biochem. Pharmacol. **1992**, *43*, 259. (c) Schaeffer, J. M.; Mrozik, H. Biochem. Pharmacol. **1992**, *43*, 259. (c) Schaeffer, J. M.; Mrozik, H. Biochem. Pharmacol. Schaeffer, J. M.; Mrozik, H. Biochem. Pharmacol. **1992**, 43, 259. (c) Schaeffer, J. M.; Mrozik, H. Biochem. Pharmacol. **1992**, 43, 259. (c) Schaeffer, J. M.; Mrozik, H. Biochem. Pharmacol. **1992**, 43, 259. (c) Schaeffer, J. M.; Mrozik, H. Biochem. Pharmacol. (c) Schaeffer, J. M.; Mrozik, H. M.; Mrozik, H. Mrozik, H. M.; Mrozik, H. M.; Mrozik, H. M.; Mr 679. (d) Shoop, W. L.; Haines, H. W.; Eary, C. H.; Michael, B. F. Am. J. Vet. Res. 1992, 53, 2032.

(7) Coles, G. C. Pestic. Sci. 1977, 8, 536.
(8) (a) Van Wyk, T. A.; Malan, F. S. Vet. Sci. 1988, 123, 226. (b) Eschevarria, F. A. M.; Trindade, N. P. Vet. Rec. 1989, 124, 147.

(9) Sanz-Cervera, J. F.; Glinka, T.; Williams, R. M. J. Am. Chem. Soc. 1993, 115, 347.

to report the first total synthesis of (+)-paraherquamide B. Key features of this synthesis include a unique application of the Somei/Kametani reaction;¹⁰ an entirely stereocontrolled intramolecular S_N2' reaction; a Pd(II)-mediated indole cyclization reaction;¹¹ a chemoselective 3° amide reduction; and a regioselective indole-to-oxindole oxidative pinacol-type rearrangement. In particular, the key intramolecular S_N2' cyclization reaction¹² (9 to 10) appears to proceed via a closed transition state¹³ where the developing chloride anion and sodium cation form a contact ion pair favoring cyclization from the "endo" (closed) conformer, giving the desired stereochemistry of the core bicyclo[2.2.2] ring system. This situation is reminiscient of the closed-transitionstate model first advanced by Denmark¹³ for the aldol condensation reaction. The piperazinone portion of the molecule starts with enal 3, easily made on large scale in seven steps from L-proline as previously reported.¹²

Enal 3 was treated with ceric ammonium nitrate (CAN) to remove the p-methoxybenzyl group (79%). The resulting amide was reduced to the alcohol with NaBH4 and protected with tertbutyldiphenylsilyl chloride to give 4. This compound was treated in a two-step, one-pot procedure with methyl chloroformate, yielding the desired imidocarbamate 5 as a variable mixture of epimers (epimerization occurs on silica gel, Scheme I).

Gramine derivative 6 was synthesized in three steps¹⁴ from the corresponding oxindole as previously reported.^{15a} When 6 and 5 were refluxed with 0.5 equiv of n-Bu₃P in acetonitrile, the desired alkylation occurred¹⁰ together with an unexpected and fortuitous decarbomethoxylation of the imidocarbamate. Indole 7 was treated with LiCl in wet HMPA at 100 °C, effecting decarbomethoxylation (obtained as a 3:1 syn:anti mixture that proved easy to separate by chromatography); both products were separately treated to the next series of manipulations. Lactim ether formation was accomplished by treating the amides with Me_3OBF_4 in CH_2Cl_2/Na_2CO_3 . The lactim ethers were then treated with (BOC)₂O followed by n-Bu₄NF to give the diols 8a and 8b. The sensitive allylic chlorides were prepared according to Corey¹⁶ (NCS and Me₂S), and the secondary alcohols carefully reprotected with tert-butyldimethylsilyl triflate to furnish the key $S_N 2'$ cyclization substrates **9a/9b**. Individual treatment of 9a/9b with 20 equiv of washed NaH in refluxing benzene effected stereoselective intramolecular S_N2' cyclization,¹² giving the desired bicyclo[2.2.2] product 10(93% from 9a; 85% from 9b). Numerous attempts to effect the proton-mediated cationic cyclization of 10 to 11 were unsuccessful; strong protic acids, Lewis acids,¹⁷ or TMSOTf failed to give even a trace of any heptacyclic indole. Treatment of 10 with Pd(II) according to Trost¹¹ [(1) PdCl₂, AgBF₄, MeCN; (2) NaBH₄, EtOH] gave the desired heptacycle

Am. Chem. Soc. 1990, 112, 808. (13) (a) Denmark, S. A.; Henke, B. R. J. Am. Chem. Soc. 1989, 111, 8032.

(b) Denmark, S. A.; Henke, B. R. J. Am. Chem. Soc. 1991, 113, 2177. (c) Magid, R. M. Tetrahedron 1980, 36, 1901.

(14) The oxindole i was prepared as described in ref 15a from vanillin and transformed into 6:



(15) (a) Williams, R. M.; Cushing, T. D. Tetrahedron Lett. 1990, 31, 6325. (b) For the first synthesis of 2H-1,5-benzodioxepin, see: Guillaumet,

G.; Coudert, G.; Loubinnoux, B. Angew. Chem. Int. Ed. Engl. 1983, 22. (16) Corey, E. J.; Kim, C. U.; Takeda, M. Tetrahedron Lett. 1972, 42, 4339-4342.

(17) (a) Guller, R.; Dobler, M.; Borschberg, H. J. Helv. Chim. Acta 1991, 74, 1636. (b) Heathcock, C. H.; Stoermer, D. J. Org. Chem. 1993, 58, 564.

© 1993 American Chemical Society

^{(10) (}a) Somei, M.; Karasawa, Y.; Kaneko, C. Heterocycles 1981, 16, 941. (b) Kametani, T.; Kanaya, N.; Ihara, M. J. Am. Chem. Soc. 1980, 102, 3974.

⁽¹¹⁾ Trost, B. M.; Fortunak, M. D. Organometallics 1982, 1, 7. (12) Williams, R. M.; Glinka, T.; Kwast, E.; Coffman, H.; Stille, J. K. J.





11 in 80% yield. A fortuitous side reaction under these conditions was the cleavage of the lactim ether. Regioselective reduction¹⁸ of the tertiary amide of 11 proceeded cleanly with AlH₃-Me₂-NEt complex and Et₃Al, followed by a NaCNBH₃ workup, to give the tertiary amine in 64–71% yield. N-Methylation of the secondary amide (NaH/MeI in DMF, 94-98%), followed by deblocking of both protecting groups (80 equiv of TFA in CH₂-Cl₂), gave the indole 12 in 59% overall yield from 11. The final oxidative spirooxidation was at first problematic but was eventually solved in a stereocontrolled manner by a two-step oxidation/ rearrangement. Although a single chloroindolenine was easily obtained from 12 with t-BuOCl and pyridine, affording the desired epimer, the final pinacol-type rearrangement was more difficult. Standard treatment¹⁹ with MeOH/H₂O/AcOH at reflux for 1 h gave only decomposition products, as did treatment with AgClO₄ and HClO₄.¹⁸ Products resulting from rearrangement/capture of a highly stabilized benzylic carbocation were observed; however, hydration of the chloroindolenine in a less polar solvent system $(90\% \text{ THF}/10\% \text{ H}_2\text{O})$ with 5 equiv of TsOH effected the desired rearrangement to the oxindole (13, 76% plus 4% of the unnatural spiroepimer). Finally, dehydration was effected with MTPI in

DMPU²⁰ to give (+)-paraherquamide B (the enantiomer of the natural product) in 83% yield. This material proved to be identical²¹ to the natural sample by ¹H NMR, MS, IR, UV, and mobility on HPLC. Use of this synthesis²² to probe the biogenesis of the paraherquamides and to expand their antiparasitic activities is currently in progress and will reported on in due course.

Acknowledgment. This work was supported by the National Institutes of Health and the National Science Foundation. We also wish to thank Dr. John Ondeyka of Merck & Co. for providing a ¹H NMR spectrum of natural paraherquamide B. J.F.S.-C. thanks the Conselleria de Educacio i Ciencia de la Generalitat Valenciana (Spain) for a fellowship.

Supplementary Material Available: Complete tabulation of spectroscopic and analytical data for all new compounds reported in this paper (20 pages). Ordering information is given on any current masthead page.

⁽¹⁸⁾ Martin, S. F.; Benage, B.; Geraci, L. S.; Hunter, J. E.; Mortimore, M. J. Am. Chem. Soc. 1991, 113, 6161.

^{(19) (}a) Williams, R. M.; Glinka, T.; Kwast, E. Tetrahedron Lett. 1989, 30, 5575. (b) Hollinshead, S. P.; Grubisha, D. S.; Bennett, D. W.; Cook, J. M. Heterocycles 1989, 29, 529. (c) Takayama, H.; Masubachi, K.; Kitajima, M.; Aimi, N.; Sakai, S. Tetrahedron Lett. 1989, 45, 1327. (d) Winterfeldt, E.; Gaskell, A. J.; Korth, T.; Radunz, H. E.; Walkowiak, M. Chem. Ber. 1969, 102, 3558-3572.

⁽²⁰⁾ Hutchins, R. O.; Hutchins, M. G.; Milewski, C. A. J. Org. Chem. 1972, 37, 4190.

⁽²¹⁾ The CD spectra of natural 1 (paraherquamide A) and synthetic 2 (paraherquamide B) were essentially mirror images, confirming the absolute stereochemistry of natural 2 as being the same as 1, which has been previously documented by single-crystal X-ray analysis of a heavy-atom (bromine) derivative (ref 2).

⁽²²⁾ All new compounds exhibited satisfactory ¹H NMR, IR, combustion analyses, and/or high-resolution mass spectral data consistent with the assigned structures.